OptimizeRx Corp

OptimizeRx Corp. is digital health company, engaging in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell on November 8, 1985 and is headquartered in Rochester, MI.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

OptimizeRx Corp exceeds revenue expectations, eyes growth through strategic deals

OptimizeRx Corp's strong revenue performance and focus on Real-World Data deals position them for growth despite challenges in revenue retention and operating expenses.
The company's strategic initiatives, including share repurchase, capacity utilization, and omnichannel expansion, showcase resilience and potential for market capture.
By leveraging RWD-AI models, focusing on strategic partnerships, and expanding service offerings, OptimizeRx aims to achieve financial and operational goals in 2023.

OptimizeRx Corp reports solid Q1 performance and eyes growth opportunities

OptimizeRx Corp (OPRX) reported solid Q1 performance, meeting revenue expectations and maintaining full-year outlook with a 10% YoY increase expected. The company showcased strengths in strategic partnerships, RWD-AI solutions, and effective use cases for RWE products.
Despite challenges in operating expenses and net revenue retention rate decline, the company is focused on innovation and growth opportunities through M&A, technology investments, and service expansion. By addressing challenges and leveraging opportunities, OptimizeRx Corp aims for sustainable growth and market differentiation.
With a strong emphasis on product execution, customer ROI, and shareholder value enhancement through a share repurchase program, OptimizeRx Corp is positioning itself for continued success in the healthcare technology sector. The company's strategic initiatives and focus on revenue diversification signal a promising outlook for future growth.

OptimizeRx Corp reports Q2 results, focuses on AI growth

OptimizeRx Corp navigated challenges in Q2 2023 with a focus on financial stability, operational efficiency, and strategic growth initiatives.
Despite disappointment with results, the company remains optimistic about the future of digital marketing in healthcare and the potential of AI-driven solutions.
With a strong balance sheet, emphasis on core business areas, and plans for cost management, OptimizeRx is positioned to capitalize on growth opportunities.
The company's commitment to renewals, upsells, and AI-driven engagement underscores a proactive approach to revenue retention and customer satisfaction.

OptimizeRx Corp (OPRX) beats Q3 expectations, eyes robust 2024 growth

OptimizeRx's Q3 performance exceeded expectations, showcasing strong financials and strategic acquisitions driving growth. While competitors face challenges, OptimizeRx is poised for further expansion and revenue increase in 2024 through enhanced platforms and market opportunities.

OptimizeRx Corp exceeds revenue expectations, eyes $100M target in 2024

OptimizeRx Corp delivered exceptional Q4 2023 results, driven by organic messaging strength and the Medicx Health acquisition.
The company's focus on digital solutions and strategic partnerships positions it well for future growth and capturing pharma spend.
While facing macroeconomic challenges, OptimizeRx's progress in Medicx Health integration and DAAP platform growth present promising opportunities.

OptimizeRx Corp reports robust Q1 performance, eyes sustained growth

OptimizeRx Corp's Q1 2024 performance reflects strong revenue growth, improved gross margin, and positive operating cash flow, underpinned by a focus on DAAP and stakeholder engagement.
While facing challenges in profitability and seasonality impact, the company remains optimistic about scaling DAAP, accelerating revenue growth, and enhancing performance in the second half of the year.
With opportunities to drive revenue through cross-selling, expanding infrastructure, and leveraging AI models, OptimizeRx is poised for sustainable growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell in 2006 and is headquartered in Waltham, MA.

WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Thursday, March 28, 2024, at 8:30 a.m. Eastern Time to discuss the preliminary, unaudited results for the fourth quarter.

OptimizeRx Sets Fourth Quarter 2023 Conference Call for March 28, 2024 at 8:30 a.m. ET

WALTHAM, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today provided an update on the anticipated timeline for its financial reporting and reaffirms prior revenue and adjusted EBITDA estimates for FY2023.

OptimizeRx Provides an Update on the Timing of Earnings Call and Reaffirms Prior Revenue and Adjusted EBITDA Estimates for FY2023

WALTHAM, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced its collaboration with Walmart to support its Specialty Pharmacies of the Community (SPOCs) provider outreach initiative.

OptimizeRx Powers Walmart's ‘Specialty Pharmacies of the Community' Outreach Effort

WALTHAM, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, is pleased to announce changes to its Board of Directors reflecting a strategic move to further align with the company's growth plans.

OptimizeRx Announces Strategic Board Changes to Support Growth and Evolving Landscape

ADMA Biologics

Arcutis Biotherapeutics

Royal Philips

Phreesia Inc

ADMA, ARQT, PHR, OPRX and PHG have been added to the Zacks Rank #1 (Strong Buy) List on January 11, 2024.

New Strong Buy Stocks for January 11th

WALTHAM, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced select preliminary unaudited financials for 2023 and is providing the following business update.

OptimizeRx Preannounces Select Expected 2023 Financials and Provides a Business Update

WALTHAM, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that executives from the Company will be presenting and participating in one-on-ones at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 8-11, 2024.

OptimizeRx to Participate at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco

OptimizeRx Corp. (OPRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

OptimizeRx Corp. (OPRX) Upgraded to Buy: What Does It Mean for the Stock?

The consensus price target hints at a 41.3% upside potential for OptimizeRx Corp. (OPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 41.25% Upside in OptimizeRx Corp. (OPRX): Here's What You Should Know

Freshpet

Pinterest

Invest in stocks such as Freshpet (FRPT), OptimizeRx (OPRX) and Pinterest (PINS) at the moment for solid earnings acceleration.

3 Stocks Worth a Buy for Superb Earnings Acceleration

OptimizeRx Corp. (OPRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why OptimizeRx Corp. (OPRX) Might be Well Poised for a Surge

The mean of analysts' price targets for OptimizeRx Corp. (OPRX) points to a 47.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in OptimizeRx Corp. (OPRX)? Wall Street Analysts Think 47.72%

OptimizeRx Corporation (NASDAQ:OPRX ) Q3 2023 Earnings Conference Call November 6, 2023 8:30 AM ET Company Participants William Febbo - Chief Executive Officer Edward Stelmakh - Chief Financial and Operating Officer Steve Silvestro - Chief Commercial Officer Marion Odence-Ford - General Counsel and Chief Compliance Officer Andrew D'Silva - Senior Vice President, Corporate Finance Conference Call Participants Thomas Schuyler - RBC Capital Markets David Grossman - Stifel Neil Chatterji - B. Riley Eric Martinuzzi - Lake Street Capital Markets Richard Baldry - ROTH Capital Partners Operator Good morning, everyone and thank you for joining OptimizeRx's Third Quarter Fiscal 2023 Earnings Discussion.

OptimizeRx Corporation (OPRX) Q3 2023 Earnings Call Transcript

- Increases guidance for 2023 and introduces guidance for 2024- Total revenue of $16.3 million- GAAP net loss per share of $(0.17)- Non-GAAP net income per share of $0.09- Total DAAP (fka RWD) deals for the year now stands at 16- Completed acquisition of Medicx Health after quarter end

OptimizeRx Reports Third Quarter 2023 Financial Results

OptimizeRx Corp. (OPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OptimizeRx Corp. (OPRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Executive Leadership expands with Steve Silvestro being promoted to President, and Theresa Greco assuming the role of Chief Commercial Officer Executive Leadership expands with Steve Silvestro being promoted to President, and Theresa Greco assuming the role of Chief Commercial Officer

OptimizeRx Announces Completion of Medicx Acquisition and Sets Third Quarter 2023 Conference Call for November 6, 2023, at 8:30 a.m. ET

OptimizeRx Corp. (OPRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

OptimizeRx Corp. (OPRX) Surges 13.0%: Is This an Indication of Further Gains?

Preannounces Preliminary Third Quarter 2023 Results OptimizeRx adds new, proven, profitable technologies to become the most comprehensive healthcare marketing platform in the nation. Consolidated revenue run rate will increase to nearly $100 million and the acquisition is expected to be immediately accretive to earnings.

OptimizeRx Announces Agreement to Acquire Medicx Health for $95 million to Expand its Omnichannel Reach to Consumers

WALTHAM, Mass., Aug. 24, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced the expansion of its AI-enabled healthcare technology platform's reach through multi-year partnerships with two leading electronic health record (EHR) providers and a telehealth platform. These partnerships are expected to be active within the platform later this year and to materially contribute to the Company's digital point-of-care (POC) reach.

OptimizeRx Expands AI Powered Omnichannel Platform

OptimizeRx Corporation. (NASDAQ:OPRX ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Edward Stelmakh - Chief Financial and Operating Officer Stephen Silvestro - Chief Commercial Officer Marion Odence-Ford - General Counsel and Chief Compliance Officer Andrew D'Silva - Senior Vice President, Corporate Finance Conference Call Participants Ryan Daniels - William Blair Sean Dodge - RBC Capital Markets Eric Martinuzzi - Lake Street Operator Good afternoon, everyone.

OptimizeRx Corporation (OPRX) Q2 2023 Earnings Call Transcript

– RWD.AI-enabled portion of the core business sees 186% YOY growth during the first half of 2023 – Non-core business is lagging – Total revenue of $13.8 million – GAAP net loss per share of $(0.24) – Non-GAAP net loss per share of $(0.01) ROCHESTER, Mich., Aug. 14, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, reported results for the three months ended June 30, 2023.

OptimizeRx Reports Second Quarter 2023 Financial Results

ROCHESTER, Mich., July 31, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy will hold a conference call on Monday, August 14, 2023 at 4:30 p.m. Eastern Time to discuss its results for the second quarter and half year period ended June 30, 2023. The financial results will be issued in a press release prior to the call.

OptimizeRx Sets Second Quarter 2023 Conference Call for August 14, 2023 at 4:30 p.m. ET

OptimizeRx Corporation provides communication technologies between pharma firms, healthcare providers, and patients. The company has seen material operating headwinds as the U.S. healthcare industry exited the pandemic and FDA approvals slowed. Until we see improving operating metrics and faster FDA approvals, I'm Neutral [Hold] on OptimizeRx Corporation.

OptimizeRx Aims For Growth After Swoon

ROCHESTER, Mich., May 24, 2023 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, provides a 2023 mid-year strategic update commenting on: 1) current revenue backlog, 2) strategic roadmap with key pillars of growth, and 3) long term financial performance aspirations through steady buildout of scalable, future proofed, enterprise solution suite.

OptimizeRx's CEO Provides 2023 Midyear Strategic Update

Castagna was recognized as a Digital Crusader for her ongoing and leading-edge work in digital access to therapies for patients Castagna was recognized as a Digital Crusader for her ongoing and leading-edge work in digital access to therapies for patients

News for OptimizeRx Corp Stock (OPRX)